Ensovibep
drugOn this page
Also known as MP-0420Mp0420
Summary
Ensovibep (CHEMBL4802171) is a phase-3 clinical-stage protein; indicated across 1 condition including severe acute respiratory syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Indications: 1 condition
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4802171 |
| Name | Ensovibep |
| Type | Protein |
| Max phase | 3 |
Also known as: Ensovibep, MP-0420, Mp0420, MP0420, ENSOVIBEP
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| CoV Spike glycoprotein | Binding |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04501978 | PHASE3 | COMPLETED | ACTIV-3: Therapeutics for Inpatients With COVID-19 |
| NCT04828161 | PHASE2/PHASE3 | TERMINATED | A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 |
| NCT05780463 | PHASE3 | COMPLETED | MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) |
| NCT04834856 | PHASE2 | COMPLETED | Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients |
| NCT04870164 | PHASE1 | TERMINATED | Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: severe acute respiratory syndrome